Restenosis Following Coronary Angioplasty: Current Status

Mun K. Hong, MD

From the Cardiac Catheterization Laboratory, New York Presbyterian Hospital - Cornell University, New York, NY

INTRODUCTION

Since introduction almost 25 years ago by Dr. Andreas Gruntzig, percutaneous transluminal coronary angioplasty (PTCA) has established itself as a viable non-surgical treatment option for patients with symptomatic coronary artery disease. With improvement in operation techniques and angioplasty equipments, especially with the availability of stents, the PTCA procedural success rate approaches over 95% in most lesions and complication rates around 1%. This remarkable procedural success, however, has not translated into sustained long-term outcomes. Restenosis or renarrowing at the site of successful PTCA has been the major limitation of this therapy since its inception. However, we now understand the mechanisms responsible for the restenosis process and have made tremendous progress in reducing the restenosis rates (Table 1). This review paper will highlight these strategies to combat restenosis.

Table 1. Mechanisms of restenosis and potential treatments

| Mechanism                      | Treatment                        | Availability |
|--------------------------------|----------------------------------|--------------|
| Acute Recoil                   | Stent                            | Yes          |
| Thrombus Deposition            | Antiplatelet therapy             | Yes          |
|                                | including glycoprotein IIb/IIIa   |              |
| Inflammation                   | Anti-inflammatory agent           | Yes          |
| Chronic Geometric Remodeling   | Stent                            | Yes          |
| Neointimal Hyperplasia         | Anti-proliferative agent/deluting stent | Undergoing investigation |
| In-stent neointimal hyperplasia| Brachytherapy                     | Yes          |

In the era of balloon angioplasty, restenosis was a frequent event, occurring in approximately 50% of patients by follow-up angiography and in about 30% of patients clinically within six months following a successful procedure[1,2]. The mechanism of restenosis, based on limited animal studies in normal vessels and human autopsy findings, was felt to be initial thrombus formation and subsequent neointimal hyperplasia[3]. This partially correct assumption led to numerous pharmacological studies targeting reduction in thrombus deposition or neointimal hyperplasia. These investigations were initially conducted in animal models of overstretch balloon injury and when the results were positive, subsequently in patients. Although the animal studies were in general encouraging, the results of randomized clinical studies were uniformly disappointing[7]. The negative results were then felt to be a dosing issue, as the weight-adjusted drug dosage was at least a log order higher in animals. Similar amounts in patients would have resulted in severe systemic side effects. Thus, there was an intense interest and research into local drug delivery. The hypothesis was that the amount of drug necessary for preventing restenosis if given systemically would be toxic to the patients, but a smaller amount of the drug delivered at the site of angioplasty using these local drug delivery catheters would provide greater efficacy[8]. This approach also failed, because the drug delivery was inefficient (less than one percent of the drug was successfully delivered to the vessel wall) and the deposited drug did not stay around for a sufficient period of time for efficacy. More importantly, these therapies were based on incorrect assumption regarding the predominant mechanism of restenosis. Finally, the initial suboptimal results, not too infrequent after balloon angioplasty, also contributed to the high restenosis rates.
Figure 1. Angiographic (top panels) and intravascular ultrasound (bottom panels) findings in a patient with ostial left anterior descending coronary artery lesion (left panels). The lesion was successfully treated with directional coronary atherectomy (DCA; middle panels). However, seven months later, the patient returned with recurrent symptoms and restenosis (right panels). Intravascular ultrasound demonstrated chronic geometric remodeling as the predominant mechanism of restenosis rather than neointimal hyperplasia. (Reproduced by permission from reference 7).

Thus, new angioplasty devices, such as directional coronary or rotational atherectomy catheters, were developed with the hope of modifying the plaque and reducing restenosis with a mechanical approach.

The results of randomized trials comparing the new angioplasty devices versus balloon angioplasty were also negative. Not until the seminal intravascular ultrasound (IVUS) observations of chronic geometric remodeling (vessel shrinkage at the site of angioplasty) being the predominant mechanism of non-stent angioplasty restenosis did we begin to understand how to address the prevention of restenosis in a logical manner (Figure 1). It became clear that a mechanical approach with vessel scaffolding, such as the metallic stents, was the only way to prevent chronic vessel shrinkage. Indeed, the randomized trials comparing the Palmaz-Schatz stents versus balloon angioplasty were the first clinical restenosis studies to provide positive results. However, even these encouraging results showed that stents reduce but do not eliminate restenosis. Subsequent studies in unfavorable lesions, such as small vessels (<3.0 mm in diameter) or diffuse lesions (>10 mm in length), showed that stents are still associated with high restenosis rates, not too dissimilar from those after balloon angioplasty.

Furthermore, IVUS observations in patients documented that in-stent restenosis is purely neointimal hyperplasia, as stents do not recoil over time (Figure 2). Thus, investigators have attempted to define the variables associated with in-stent restenosis. These studies, especially with the aid of IVUS, showed that ostial location, pre-intervention plaque burden and post-intervention lumen dimensions assessed by IVUS, and diabetes mellitus were predictors of eventual in-stent restenosis. Thus, the stent implantation techniques evolved to high-pressure adjunct balloon angioplasty to optimize the initial stent implantation. However, refined techniques still cannot modify the restenosis rates at the ostial location or in diabetic patients. Furthermore, for those lesions not amenable to stent implantation, the restenosis rate is still unacceptably high.

RESTENOSIS: PRESENT

It is clear that stents are the only angioplasty device to have an impact on restenosis. However, there are still unfavorable lesion subsets, such as small vessels, diffuse lesions, ostial lesions, saphenous vein graft lesions and diabetic population whose restenosis rates have not been altered by stents. Especially for these lesions, new approaches, such as drug-coated stents and intravascular brachytherapy, are actively investigated to reduce restenosis.
The most exciting development has been the drug-coated stents. The rationale for this approach is that the metallic stent would provide the scaffolding to prevent geometric remodeling and that the antiproliferative agent impregnated on the stent platform would prevent neointimal hyperplasia, thus addressing both mechanisms of restenosis with the same device. Despite the theoretical difficulties of finding biocompatible polymers for drug impregnation, drugs effective at low dose, and unknown pharmacokinetics, there have been encouraging animal studies. Based on these results, the rapamycin-coated stents have been studied in 30 patients with de novo single vessel disease. The results of this preliminary registry study have been astounding, with no angiographic or clinical restenosis at one-year follow-up. This stent as well as other drug-eluting stents, such as paclitaxel-coated stents and actinomycin-eluting stents, are undergoing randomized trials against bare metal stents to determine the efficacy of this approach for the prevention of restenosis. Whether this therapy would be effective in unfavorable lesions is not known.

Another novel approach, which has been more successful in treating the in-stent restenosis than the prevention of restenosis for de novo lesions, is the intravascular brachytherapy. The mechanism of brachytherapy is that the ionizing radiation would prevent the dividing cells, such as the smooth muscle cells causing the neointimal hyperplasia, from proliferation by damaging the nucleus of the cells. Several randomized trials have documented the beneficial effect of this approach with both gamma and beta radiation in reducing the recurrent in-stent restenosis. The preliminary result of the beta radiation for prevention of restenosis following angioplasty of de novo lesions has been discouraging. However, whether gamma radiation or different beta system would prevent the initial restenosis, especially in combination with stents, needs further evaluation.

R E S T E N O S I S : F U T U R E

Future efforts should try to prevent restenosis completely rather than merely reduce the rates. This may involve a combination of mechanical devices and adjunct pharmacology. The restenosis process is a culmination of multiple factors, including the initial thrombus formation, inflammation, geometric remodeling and neointimal hyperplasia. Potent pharmacological agents could prevent the first two processes, stents would prevent the third event and effective antiproliferative agents, ideally from the stent platform, could address the last process. Potentially more effective drug-eluting stent platform may be drug impregnation of stent grafts, as the graft material would allow impregnation of the drug in a much larger area (close to 90% of the lesion area versus 15-20% for bare metal stents). This device would have limited use in native coronary arteries, however, due to the presence of many side branches and the occlusion of these branches by the graft material.

Alternatively, the angioplasty procedure may have to prevent only the recurrence of ischemia in the target vessel, even if the angioplasty site should become renarrowed. This approach may involve the drug-eluting stent and administration of angiogenic growth factors or gene therapy to myocardium supplied by the treated vessel. Thus, even if the stent should become restenosed, the angiogenesis in the target area may prevent the occurrence of ischemia and the need for repeat intervention.

C O N C L U S I O N S

The restenosis process is an uncontrolled progression of the natural healing process. Thus, therapies aimed at allowing the necessary healing to occur (i.e., re-endothelialization) and yet preventing the excess scarring (both adventitial and intimal) could prevent restenosis. With rapidly evolving technologies and continuing research, restenosis will be prevented in the majority of patients in the near future and the minority with restenosis still may benefit from a combination therapy aimed at preventing ischemia, not necessarily restenosis.

R E F E R E N C E S

1. Semys PW, Luiken HE, Beatt KD, Geuskens R, Feyter PJ, van den Brand M, Reiber JH, ten Kanten UJ, Van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. Circulation 77:361-371, 1988
2. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Heno K, Yokoi H, Hamasaki N, Honuchi H, Ohashi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 2:656-622, 1988
3. Steele PM, Cheshbro JH, Stanson AW, Holmes DR Jr, Dewaumee MK, Badimon L, Fuster V. Balloon angioplasty: natural history of the pathophysiological
response to injury in a pig model. Circ Res 57:105-12, 1985

4. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 82:290-220, 1990

5. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 6:369-375, 1985

6. Farb A, Vimpani R, Atkinson JB, Kloodie FD. Plaque morphology and pathologic changes in arteries from patients dying after coronary balloon angioplasty. J Am Coll Cardiol 16:421-429, 1990

7. Hong MK, Mehan R, Mintz GS, Leon MB. Restenosis after coronary angioplasty. Current Problems in Cardiology 22:1-36, 1997

8. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: fact, fancy, and future. Circulation 90:2070-2084, 1994

9. Hinohara T, Rowe MH, Robertson GC, Selmon MR, Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S, Di Francesco L, Colombo A. Angiographic and clinical outcome following coronary stenting of small vessels. A comparison with coronary stenting of large vessels. J Am Coll Cardiol 32:1610-1618, 1998

10. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bueher TA, Hong MK, Popma JJ, Leon MB. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 95:1247-1254, 1998

11. Hoffmann R, Mintz GS, Mehan R, Pichard AD, Kent KM, Satler LF, Popma JJ, Wu H, Leon MB. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol 3:133-49, 1998

12. Komowski R, Mintz GS, Kent KM, Pichard AP, Satler LF, Buecher TA, Hong MK, Popma JJ, Leon MB. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 94:1247-1254, 1996

13. Klugherz BD, Llanos G, Lieuallen W, et al. Randomized comparison of angioplasty of complex coronary lesions at a single center: excimer laser, rotational atherectomy, and balloon comparison (ERBAC) study. Circulation 84:632-643, 1991

14. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Korach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 94:43-53, 1996

15. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Pein L, Dette K, Vetri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 333:486-501, 1994

16. Semuy PW, de Jaegere P, Kemeneny F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 333:486-495, 1994
26. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA, Guarnieri EN, Steutenman S. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 336:1697-1703, 1997

27. Waksman R, White RL, Chan RC, Bass BG, Gerlach L, Mintz GS, Satler LF, Mehran R, Serruys PW, Lansky AJ, Fitzgerald P, Bhargava B, Kent KM, Pichard AD, Leon MB. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 101:165-171, 2000

28. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, Wong SC, Fish D, Kuntz RE. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 344:250-256, 2001

29. Raizner AE, Oesterle SN, Waksman R, Serruys PW, Colombo A, Lim YL, Yeung AC, van der Giessen Wj, Vandevier L, Chiu JK, White LR, Fitzgerald PJ, Kaluzka, GL, Ali NM. Inhibition of restenosis with beta-emitting radiotherapy: Report of the proliferation reduction with vascular energy trial (PREVENT). Circulation 102:951-958, 2000

30. Kuntz R. Late breaking trials. American College of Cardiology 2001

31. Rosengart TK, Lee LY, Patel SR, Sanborn SR, Sanborn TA, Parkh M, Bergman GW, Hachamovitch R, Szuz M, Klugfield Pd, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, kom OW, Crystal RG. Angiogenesis gene therapy. Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF21 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468-474, 1999